Synagis
Company: MedImmune
Approval Status: Approved June 1998
Treatment for: respiratory syncytial virus (RSV)
Areas: Pulmonary/Respiratory Diseases
General Information
Other Useful Resources
Synagis has been approved for the prevention of serious lower respiratory tract disease in pediatric patients at high risk of RSV disease. Synagis is the first monoclonal antibody to be licensed for any infectious disease. It is injected intramuscularly in a doctor's office.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
Medical Dictionary Searches
